The pneumonia vaccine is a shot that protects against infections caused by a type of bacteria called pneumococcus, one of the most common causes of pneumonia, bloodstream infections, and meningitis. Several versions of the vaccine exist, each covering a different number of bacterial strains. The vaccine is routinely recommended for all children under 5 and for adults starting at age 50, with earlier vaccination for people who have certain medical conditions.
What the Vaccine Actually Protects Against
Pneumococcal bacteria can cause more than just pneumonia. They’re responsible for ear infections in children, sinus infections, and two life-threatening conditions: bacteremia (bacteria in the bloodstream) and bacterial meningitis (infection of the tissue surrounding the brain and spinal cord). The vaccine doesn’t cover every possible cause of pneumonia, since viruses and other bacteria can also cause it. But it targets the bacterial species behind some of the most severe and common cases.
There are over 90 types of pneumococcal bacteria. The vaccines available today cover the strains most likely to cause serious illness. PCV15 covers 15 strains, PCV20 covers 20, PCV21 covers 21, and PPSV23 covers 23. These numbers matter because a vaccine with broader strain coverage can prevent a wider range of infections.
How the Two Vaccine Types Work Differently
Pneumococcal vaccines come in two basic designs: conjugate vaccines (the PCV series) and polysaccharide vaccines (PPSV23). They train your immune system in meaningfully different ways.
Polysaccharide vaccines use sugar molecules from the bacteria’s outer coating to trigger an immune response. This response relies on one branch of the immune system alone and primarily prevents bacteria from spreading through the bloodstream. It works reasonably well in healthy adults but doesn’t generate strong immune memory or protect the lining of the nose and throat where bacteria first take hold.
Conjugate vaccines attach those same sugar molecules to a protein carrier. This recruits a second branch of the immune system, producing longer-lasting memory cells and generating protection at the mucosal surfaces of the airways. That mucosal immunity is what reduces the chance of carrying and spreading the bacteria in the first place. This is also why conjugate vaccines work well in infants and young children, whose immune systems don’t respond effectively to the polysaccharide design alone.
Who Should Get Vaccinated
Children Under 5
All children are recommended to receive a four-dose series of a conjugate vaccine (PCV15 or PCV20) at 2 months, 4 months, 6 months, and 12 to 15 months. Children who miss doses or start the series late can still catch up, though the number of doses needed depends on how old they are when they begin.
Adults 50 and Older
As of late 2024, adults 50 and older who have never received a pneumococcal vaccine are recommended to get a single dose of PCV20, PCV21, or PCV15. If PCV15 is used, a follow-up dose of PPSV23 is needed at least one year later to broaden coverage. Adults 65 and older who previously received only the older PCV13 vaccine are recommended to get an updated dose of PCV20 or PCV21 at least one year after their last shot.
If you’ve already completed a full series with both PCV13 and PPSV23 at age 65 or later, the decision about whether to get a newer vaccine like PCV20 or PCV21 is something to discuss with your doctor, since the added benefit is smaller when you’ve already had broad coverage.
Younger Adults With Higher Risk
Adults aged 19 to 49 qualify for pneumococcal vaccination earlier if they have conditions that weaken the immune system, a cochlear implant, or a cerebrospinal fluid leak. Other chronic conditions like heart disease, lung disease, diabetes, liver disease, and smoking also raise pneumococcal risk and may qualify someone for earlier vaccination. The specific schedule and number of doses depends on what vaccines you’ve already had and what your underlying condition is.
What to Expect After the Shot
Side effects are common but mild and typically resolve within a day or two. The most frequent reaction across all the vaccine types is pain at the injection site, reported by 50 to 80% of recipients depending on the specific vaccine. Swelling at the injection site occurs in roughly 10 to 30% of people.
Beyond the arm soreness, fatigue affects 21 to 40% of adults, muscle aches affect 11 to 50%, and headache occurs in 18 to 30%. These ranges vary by vaccine type, with PCV15 tending toward the higher end for muscle aches and fatigue, and PCV21 at the lower end. Fever is uncommon in adults (under 1%) but more frequent in infants and toddlers, where 24 to 35% develop a mild fever within the first week.
Serious adverse reactions are rare. The main reason to avoid or delay the vaccine is a known severe allergic reaction to a previous dose or to a component of the vaccine, or if you’re moderately to severely ill at the time of your appointment. A mild cold or low-grade illness is generally not a reason to postpone.
How Many Doses Adults Need
Most healthy adults need just one dose. If you’ve never had any pneumococcal vaccine and you’re 50 or older, a single shot of PCV20 or PCV21 completes the series. If PCV15 is the vaccine available to you, one dose of PPSV23 follows at least a year later.
For adults with immune-compromising conditions who previously received PCV13 and PPSV23, a dose of PCV20 or PCV21 is recommended at least five years after the most recent pneumococcal shot. After that, the series is considered complete. Unlike some other vaccines, pneumococcal vaccines do not currently require regular boosters on a set cycle. The protection from conjugate vaccines, in particular, is considered durable because of the immune memory they generate.
Choosing Between Vaccine Options
The practical differences come down to how many bacterial strains each vaccine covers and how many doses you’ll need. PCV20 and PCV21 are both single-dose options with broad strain coverage, making them the most straightforward choice for adults. PCV15 covers fewer strains and requires a second shot (PPSV23) to fill the gap. PPSV23 on its own is no longer the preferred first vaccine for anyone, though it still plays a role as a follow-up to PCV15.
Your doctor may recommend one over another based on what’s available, what you’ve had before, and your specific risk factors. If you’re starting from scratch, a single dose of PCV20 or PCV21 is the simplest path to broad protection.